nalmefene HCl

Phase 1Small molecule

PPurdue Pharma LP

nalmefene HCl is one of 24 small molecule programs targeting Pathological Gambling. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pathological GamblingActive, not recruiting

Respiratory DepressionActive, not recruiting

Pathological GamblingPhase 2/Phase 3

Active, not recruiting

Respiratory DepressionPhase 1

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Respiratory Depression

#DrugCompanyPhaseTrials

Narcan

SScienture

Approved

2 2

Anerem

AAcacia Pharma Ltd

Approved

1 3

Duragesic

CCephalon

Approved

1 4

MS Contin

HHikma Pharmaceuticals LLC

Tylenol

1 6

Selincro

IIndivior Inc.

Phase 3

1 7

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

1 8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

3 9

Fentanyl, Dexmedetomidine

UUniversity of Saskatchewan

Phase 3

1 10

Acetaminophen, Gabapentin

UUniversity of Saskatchewan

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Respiratory Depression

NCT05338632

Clinical

Trials by Indication[1]

Pathological Gambling1 trial

Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling

Completed·SSomaxon Pharmaceuticals·Phase 2/3·NCT00132119·233 enrolled

Respiratory Depression1 trial

Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists

Recruiting·LLeiden University Medical Center·Phase 1·NCT05338632·24 enrolled

MPA1 trial

Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg

Completed·PPurdue Pharma LP·Phase 1·NCT06719986·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for nalmefene HCl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nalmefene HCl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nalmefene HCl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Purdue Pharma LP company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPurdue Pharma LP

nalmefene HCl

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Pathological Gambling1 trial

Respiratory Depression1 trial

MPA1 trial

References

Drug Info

Quick Facts

Related News